Clinical Experience With Certican® (Everolimus) in Maintenance Heart Transplant Patients at the Medical University of Vienna

This publication has 12 references indexed in Scilit:

• Sirolimus in De Novo Heart Transplant Recipients Reduces Acute Rejection and Prevents Coronary Artery Disease at 2 Years
  Circulation, 2004
• Immune and Nonimmune Predictors of Cardiac Allograft Vasculopathy Onset and Severity: Multivariate Risk Factor Analysis and Role of Immunosuppression
  American Journal of Transplantation, 2004
• Immunosuppression: practice and trends
  American Journal of Transplantation, 2004
• Mycophenolate mofetil for secondary prevention of cardiac allograft vasculopathy: influence on inflammation and progression of intimal hyperplasia
  The Journal of Heart and Lung Transplantation, 2004
• Low toxicity immunosuppressive protocols in renal transplantation
  The Keio Journal of Medicine, 2004
• Immunosuppression in pediatric heart transplantation: 2003 and beyond
  Current Treatment Options in Cardiovascular Medicine, 2003
• Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients
  New England Journal of Medicine, 2003
• Population pharmacokinetics of everolimus in de novo renal transplant patients: Impact of ethnicity and comedications
  Clinical Pharmacology & Therapeutics, 2001
• A RANDOMIZED ACTIVE-CONTROLLED TRIAL OF MYCOPHENOLATE MOFETIL IN HEART TRANSPLANT RECIPIENTS1
  Transplantation, 1998
• SDZ RAD, A NEW RAPAMYCIN DERIVATIVE
  Transplantation, 1997